Robert Brooke


Vitality Biopharma, Inc.

About Robert

Robert Brooke is the CEO and co-founder of Vitality Biopharma, a drug development company dedicated to unlocking the power of cannabinoids for treatment of serious neurological and inflammatory conditions. Previously, he was the founder of a cancer drug development company that is now known as Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Mr. Brooke is also a co-founder and serves on a limited part-time basis as the CEO of Intervene Immune, Inc. From 2004 to 2008, he was an analyst with Bristol Capital Advisors, LLC, investment manager to Bristol Investment Fund, Ltd. During this period, Bristol financed over 60 public healthcare and life science companies, and was listed by The PIPEs Report in 2005 as being the most active investor in private placements by public biotechnology companies. Mr. Brooke has a BS in electrical engineering from Georgia Tech and an MS in biomedical engineering from UCLA.

Robert's Videos

The North American cannabis market is a competitive industry, but cannabis industry ancillary businesses fill less crowded spaces and provide essential services around the industry. This panel will discuss different ancillary businesses models that are attractive investment opportunities.
In 2018, the United States cannabis industry recorded significant growth and this is a trend that we expect to continue for years to come. This panel features leading expects focused on all facets of the United stated cannabis industry. The recent pullback has created a great opportunity for new investors and this is a discussion that cannot be missed.

From biotech to edibles, consulting to technology, the legal cannabis industry offers U.S. investors significant investment opportunities. this panel of experts features executives from cannabis companies that are capitalizing on the United States cannabis industry and will discuss some of the way investors can capitalize on the burgeoning cannabis sector.

Live Now

Accredited Investors Virtual Expo

March 2 - 4, 2021